|
1
|
Haugen BR and Sherman SI: Evolving
approaches to patients with advanced differentiated thyroid cancer.
Endocr Rev. 34:439–455. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wells SA Jr and Santoro M: Update: The
status of clinical trials with kinase inhibitors in thyroid cancer.
J Clin Endocrinol Metab. 99:1543–1555. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hajighasemi F and Mirshafiey A: In vitro
sensitivity of leukemia cells to propranolol. J Clin Med Res.
1:144–149. 2009.PubMed/NCBI
|
|
4
|
Liao X, Che X, Zhao W, Zhang D, Bi T and
Wang G: The β-adrenoceptor antagonist, propranolol, induces human
gastric cancer cell apoptosis and cell cycle arrest via inhibiting
nuclear factor κB signaling. Oncol Rep. 24:1669–1676.
2010.PubMed/NCBI
|
|
5
|
Wolter JK, Wolter NE, Blanch A, Partridge
T, Cheng L, Morgenstern DA, Podkowa M, Kaplan DR and Irwin MS:
Anti-tumor activity of the beta-adrenergic receptor antagonist
propranolol in neuroblastoma. Oncotarget. 5:161–172.
2014.PubMed/NCBI
|
|
6
|
Wolter NE, Wolter JK, Enepekides DJ and
Irwin MS: Propranolol as a novel adjunctive treatment for head and
neck squamous cell carcinoma. J Otolaryngol Head Neck Surg.
41:334–344. 2012.PubMed/NCBI
|
|
7
|
Zhang D, Ma Q, Shen S and Hu H: Inhibition
of pancreatic cancer cell proliferation by propranolol occurs
through apoptosis induction: The study of beta-adrenoceptor
antagonist's anticancer effect in pancreatic cancer cell. Pancreas.
38:94–100. 2009. View Article : Google Scholar
|
|
8
|
Zhang D, Ma QY, Hu HT and Zhang M:
β2-adrenergic antagonists suppress pancreatic cancer cell invasion
by inhibiting CREB, NFκB and AP-1. Cancer Biol Ther. 10:19–29.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Powe DG, Voss MJ, Zänker KS, Habashy HO,
Green AR, Ellis IO and Entschladen F: Beta-blocker drug therapy
reduces secondary cancer formation in breast cancer and improves
cancer specific survival. Oncotarget. 1:628–638. 2010. View Article : Google Scholar
|
|
10
|
Barron TI, Connolly RM, Sharp L, Bennett K
and Visvanathan K: Beta blockers and breast cancer mortality: A
population-based study. J Clin Oncol. 29:2635–2644. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
De Giorgi V, Grazzini M, Gandini S,
Benemei S, Lotti T, Marchionni N and Geppetti P: Treatment with
β-blockers and reduced disease progression in patients with thick
melanoma. Arch Intern Med. 171:779–781. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kelly PN and Strasser A: The role of Bcl-2
and its pro-survival relatives in tumourigenesis and cancer
therapy. Cell Death Differ. 18:1414–1424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Serasinghe MN, Missert DJ, Asciolla JJ,
Podgrabinska S, Wieder SY, Izadmehr S, Belbin G, Skobe M and Chipuk
JE: Anti-apoptotic BCL-2 proteins govern cellular outcome following
B-RAFV600E inhibition and can be targeted to reduce
resistance. Oncogene. 34:857–867. 2015. View Article : Google Scholar
|
|
14
|
Oltersdorf T, Elmore SW, Shoemaker AR,
Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges
J, Hajduk PJ, et al: An inhibitor of Bcl-2 family proteins induces
regression of solid tumours. Nature. 435:677–681. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang X, Tang N, Hadden TJ and Rishi AK:
Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta.
1813:1978–1986. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Datta SR, Dudek H, Tao X, Masters S, Fu H,
Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples
survival signals to the cell-intrinsic death machinery. Cell.
91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Musgrove EA, Caldon CE, Barraclough J,
Stone A and Sutherland RL: Cyclin D as a therapeutic target in
cancer. Nat Rev Cancer. 11:558–572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Feine U, Lietzenmayer R, Hanke JP, Wöhrle
H and Müller-Schauenburg W: 18FDG whole-body PET in differentiated
thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I.
Nuklearmedizin. 34:127–134. 1995.In German. PubMed/NCBI
|
|
20
|
Cragg MS, Jansen ES, Cook M, Harris C,
Strasser A and Scott CL: Treatment of B-RAF mutant human tumor
cells with a MEK inhibitor requires Bim and is enhanced by a BH3
mimetic. J Clin Invest. 118:3651–3659. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Drell TL IV, Joseph J, Lang K, Niggemann
B, Zaenker KS and Entschladen F: Effects of neurotransmitters on
the chemokinesis and chemotaxis of MDA-MB-468 human breast
carcinoma cells. Breast Cancer Res Treat. 80:63–70. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sastry KSR, Karpova Y, Prokopovich S,
Smith AJ, Essau B, Gersappe A, Carson JP, Weber MJ, Register TC,
Chen YQ, et al: Epinephrine protects cancer cells from apoptosis
via activation of cAMP-dependent protein kinase and BAD
phosphorylation. J Biol Chem. 282:14094–14100. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sloan EK, Priceman SJ, Cox BF, Yu S,
Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas
BD, Wu L, et al: The sympathetic nervous system induces a
metastatic switch in primary breast cancer. Cancer Res.
70:7042–7052. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Masur K, Niggemann B, Zanker KS and
Entschladen F: Norepinephrine-induced migration of SW 480 colon
carcinoma cells is inhibited by beta-blockers. Cancer Res.
61:2866–2869. 2001.PubMed/NCBI
|
|
25
|
Melhem-Bertrandt A, Chavez-Macgregor M,
Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD,
Hortobagyi GN and Gonzalez-Angulo AM: Beta-blocker use is
associated with improved relapse-free survival in patients with
triple-negative breast cancer. J Clin Oncol. 29:2645–2652. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Söderlund V, Larsson SA and Jacobsson H:
Reduction of FDG uptake in brown adipose tissue in clinical
patients by a single dose of propranolol. Eur J nucl Med Mol
Imaging. 34:1018–1022. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Agrawal A, Nair N and Baghel NS: A novel
approach for reduction of brown fat uptake on FDG PET. Br J Radiol.
82:626–631. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kang F, Ma W, Ma X, Shao Y, Yang W, Chen
X, Li L and Wang J: Propranolol inhibits glucose metabolism and
18F-FDG uptake of breast cancer through
posttranscriptional downregulation of hexokinase-2. J Nucl Med.
55:439–445. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mathupala SP, Ko YH and Pedersen PL:
Hexokinase II: Cancer's double-edged sword acting as both
facilitator and gatekeeper of malignancy when bound to
mitochondria. Oncogene. 25:4777–4786. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Patra KC, Wang Q, Bhaskar PT, Miller L,
Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, et al:
Hexokinase 2 is required for tumor initiation and maintenance and
its systemic deletion is therapeutic in mouse models of cancer.
Cancer Cell. 24:213–228. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yu XM, Lo CY, Chan WF, Lam KY, Leung P and
Luk JM: Increased expression of vascular endothelial growth factor
C in papillary thyroid carcinoma correlates with cervical lymph
node metastases. Clin Cancer Res. 11:8063–8069. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Storch CH and Hoeger PH: Propranolol for
infantile haemangiomas: Insights into the molecular mechanisms of
action. Br J Dermatol. 163:269–274. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Filippi L, Dal Monte M, Casini G, Daniotti
M, Sereni F and Bagnoli P: Infantile hemangiomas, retinopathy of
prematurity and cancer: A common pathogenetic role of the
β-adrenergic system. Med Res Rev. 35:619–652. 2015. View Article : Google Scholar
|
|
34
|
McFarland DC and Misiukiewicz KJ:
Sorafenib in radioactive iodine-refractory well-differentiated
metastatic thyroid cancer. Onco Targets Ther. 7:1291–1299. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Champa D, Russo MA, Liao XH, Refetoff S,
Ghossein RA and Di Cristofano A: Obatoclax overcomes resistance to
cell death in aggressive thyroid carcinomas by countering Bcl2a1
and Mcl1 overexpression. Endocr Relat Cancer. 21:755–767. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Broecker-Preuss M, Viehof J, Jastrow H,
Becher-Boveleth N, Fuhrer D and Mann K: Cell death induction by the
BH3 mimetic GX15-070 in thyroid carcinoma cells. J Exp Clin Cancer
Res. 34:692015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sood AK, Bhatty R, Kamat AA, Landen CN,
Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S and Cole SW:
Stress hormone-mediated invasion of ovarian cancer cells. Clin
Cancer Res. 12:369–375. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shan T, Ma Q, Zhang D, Guo K, Liu H, Wang
F and Wu E: β2-adrenoceptor blocker synergizes with gemcitabine to
inhibit the proliferation of pancreatic cancer cells via apoptosis
induction. Eur J Pharmacol. 665:1–7. 2011. View Article : Google Scholar : PubMed/NCBI
|
